Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Nicole Liang
Institution:
Baylor College of Medicine
Observed institution:
Baylor College of Medicine
ORCID:
0009-0009-7459-8360
Observed ORCID:
0009-0009-7459-8360
OpenAlex ID:
A5132625812
Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1 -Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
·
Cancer Research
·
3
Supplemental Figure 3 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Table 6 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Figure 11 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Figure 17 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Figure 7 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Data from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Table 4 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Figure 13 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Figure 2 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Table 2 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Table 5 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Figure 9 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Figure 12 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Table 3 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Figure 10 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Figure 8 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Figure 1 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Table 7 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Table 8 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Figure 14 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Figure 16 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Figure 4 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Figure 5 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Supplemental Figure 15 from Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer
2026
·
Sarah K. Herzog
, Jessica H. Stevens
, et al.
Show more works
View as search
Works count:
30
Citation count:
3
H-index:
1
I10-index:
Year
Topic
Type